SGMO Sangamo Therapeutics Inc.

Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif.--(BUSINESS WIRE)--

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13th at 5:20pm EST.

The virtual session will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under . The presentation will also be available on the Sangamo website after the event.

About Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and genome regulation. For more information about Sangamo, visit .

EN
05/01/2021

Underlying

SGMOSangamo Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sangamo Therapeutics Inc.

 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR ...

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed wi...

September 4, 2025 1 EN
 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Reports Recent Business Highlights and Second Qua...

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain. Expect to dose first patient in fall of 2025, with preliminary proof of efficacy data anticip...

August 7, 2025 1 EN
 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should reg...

July 31, 2025 1 EN
 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Qua...

RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and fourth quarter and full year 2024 financial results. “I am pleased with Sangamo’s pipeline progress since the start of 2024. We advanced our two prioritized neurology therapies towards the clinic, securing our first ever neurology IND; we showed we are a collaborator of choice for neurotropic capsids, with the announcement of two blue-chip pharma agreements for our STAC-BBB capsid, with negotiations advancing for a third potential agreement; ...

March 17, 2025 1 EN
 PRESS RELEASE
Free
SGMO Sangamo Therape...

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earni...

RICHMOND, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference. Fourth Quarter and Full Year 2024 Earnings Results The company will hold its fourth quarter and full year 2024 results conference call at 4:30 p.m. Eastern on Monday, March 17, which will remain open to the public. During the conference call, the co...

March 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch